Fig. 1

Characterization of sorafenib resistant phenotypes. a and b, Parental and resistant Hep3b or Huh7 cells were transiently exposed to 2 µM sorafenib for indicated time points and subjected to proliferation (a) and wound-healing (b) assays using IncuCyte proliferation/migration assay. Data represents two independent experiments. (c), Parental and resistant Hep3b or Huh7 cells were transiently treated with 2 µM sorafenib for 72 h, and flow cytometry was used to measure apoptotic cells shown as percentage change. Graphs are the quantification of apoptotic cells shown as mean values ± S.D. from three independent experiments. (d), CCK-8 assays were used to measure cell viability upon exposure of parental and resistant Hep3b or Huh7 cells to 2 µM sorafenib for 72 h. Data represents two independent experiments with 8 repeats in total. (e), Oncosphere assays in parental and resistant Hep3b cells growing in medium with or without drug. Data represents three independent experiments. (f), IncuCyte proliferation assay in parental, resistant Hep3b or Huh7 cells growing in drug free medium (g), IncuCyte proliferation assays in parental, resistant or release (resistant cells growing in drug free medium for 14 days) Hep3b or Huh7 cells treated with sorafenib for indicated time points. *P < 0.05; ns, not significant; Con, control